Stock Research for CORT


Featured Broker: Ally Invest

Get the due diligence for another stock.


CORT Stock Chart & Research Data

The CORT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CORT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


CORT Due diligence Resources & Stock Charts

The CORT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CORT Detailed Price Forecast - CNN Money CNN View CORT Detailed Summary - Google Finance
Yahoo View CORT Detailed Summary - Yahoo! Finance Zacks View CORT Stock Research & Analysis -

Stock Analysis

TradeIdeas View CORT Trends & Analysis - Trade-Ideas Barrons View CORT Major Holders - Barrons
NASDAQ View CORT Call Transcripts - NASDAQ Seeking View CORT Breaking News & Analysis - Seeking Alpha
Spotlight View CORT Annual Report - OTC Report View CORT OTC Short Report -
TradeKing View CORT Fundamentals - TradeKing Charts View CORT SEC Filings - Bar Chart
WSJ View Historical Prices for CORT - The WSJ Morningstar View Performance/Total Return for CORT - Morningstar
MarketWatch View the Analyst Estimates for CORT - MarketWatch CNBC View the Earnings History for CORT - CNBC
StockMarketWatch View the CORT Earnings - StockMarketWatch MacroAxis View CORT Buy or Sell Recommendations - MacroAxis
Bullish View the CORT Bullish Patterns - American Bulls Short Pains View CORT Short Pain Metrics -

Social Media Mentions

StockTwits View CORT Stock Mentions - StockTwits PennyStocks View CORT Stock Mentions - PennyStockTweets
Twitter View CORT Stock Mentions - Twitter Invest Hub View CORT Investment Forum News - Investor Hub
Yahoo View CORT Stock Mentions - Yahoo! Message Board Seeking Alpha View CORT Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for CORT - Insider Cow View Insider Transactions for CORT - Insider Cow
CNBC View CORT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CORT - OTC Markets
Yahoo View Insider Transactions for CORT - Yahoo! Finance NASDAQ View Institutional Holdings for CORT - NASDAQ

Stock Charts

FinViz View CORT Stock Insight & Charts - StockCharts View CORT Investment Charts -
BarChart View CORT Stock Overview & Charts - BarChart Trading View View CORT User Generated Charts - Trading View

Latest Financial News for CORT

Corcept Therapeutics Incorporated (NASDAQ:CORT) Has Attractive Fundamentals, Here’s Why
Posted on Tuesday June 19, 2018

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a company with exceptional fundamental characteristics. Upon building up an investment case for a stock, we should look at various aspects. In the case ofRead More...

Today's Research Reports on Trending Tickers: Corcept Therapeutics and CRISPR Therapeutics
Posted on Tuesday June 19, 2018

NEW YORK, NY / ACCESSWIRE / June 19, 2018 / U.S. markets finished mostly lower on Monday, with the Dow logging its 5th straight decline, on fears of growing trade tensions between the U.S. and China. The ...

Corcept Therapeutics (CORT) Up 6.6% Since Earnings Report: Can It Continue?
Posted on Thursday June 07, 2018

Corcept Therapeutics (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Corcept Therapeutics Announces Positive Relacorilant Data at the 2018 American Society of Clinical Oncology Meeting
Posted on Monday June 04, 2018

Corcept Therapeutics Incorporated (CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, announced that it is presenting preliminary data from the Phase 1/2 study of its proprietary, selective cortisol modulator, relacorilant, in combination with nab-paclitaxel (Celgene Corporation’s drug, Abraxane®) to treat patients with solid tumors. The data will be exhibited today in a poster at the 2018 American Society of Clinical Oncology (ASCO) Meeting in Chicago, Illinois (June 1 – 5). “Data from the initial, dose-finding portion of this trial are striking,” said Robert S. Fishman, MD, Corcept’s Chief Medical Officer.

Enter a stock symbol to view the stock details.